GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion).
Pfizer reaches a global agreement with AbbVie
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under the terms of the agreements, AbbVie grants Pfizer a non-exclusive patent license for the use and sale of Pfizer's proposed adalimumab biosimilar for many countries around the world.
FDA grants breakthrough device designation to artificial intelligence software for CTEPH pattern recognition from Bayer and MSD
- Details
- Category: Bayer
Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Pattern Recognition, which Bayer is currently developing jointly with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA).
Sanofi builds focus on rare blood disorders and cancers
- Details
- Category: Sanofi
Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research as scientists look for new treatments for serious and life-threatening conditions. To help meet this need, Sanofi has significantly increased its focus on hematology, making a number of important investments to advance
U.S. FDA approves Larotrectinib, the first TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion
- Details
- Category: Bayer
The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of adult and pediatric patients with solid tumors with a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation that are either metastatic or where surgical resection will likely result in severe morbidity, and
Alcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and London
- Details
- Category: Novartis
Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of Novartis to execute a tax-neutral, 100% spinoff of the Alcon business. If the transaction proceeds, shares in Alcon Inc. will be listed on the SIX Swiss Exchange (SIX) and the New York Stock Exchange (NYSE) under the ticker symbol "ALC".
Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to ReviveMed, Strand Therapeutics
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today announced that ReviveMed and Strand Therapeutics are the winners of Bristol-Myers Squibb's 2018 Golden Tickets for LabCentral.
More Pharma News ...
- Novartis rises to second place in 2018 Access to Medicine Index
- Syntropy to unlock the value of scientific data in fight to end cancer
- Merck and Pfizer provide update on avelumab in platinum-resistant/refractory ovarian cancer
- MSD is looking for a digital health solution to empower oncologists by keeping them updated in their field
- Lilly submits New Drug Application to the FDA for lasmiditan for acute treatment of migraine, receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for prevention of episodic cluster headache
- Abbott recommends rejection of below-market mini-Ttender offer by Baker Mills LLC
- AstraZeneca to divest US Synagis rights to Sobi